‘Mea culpa’: What Goldman Sachs analysts got wrong about Medtronic in 2022

Goldman Sachs analysts have issued a “mea culpa” that outlines problems with recent forecasts they made about Medtronic and LivaNova.
The analysts correctly identified that Medtronic’s key pipeline projects could face setbacks, but they said they underestimated how hard subsequent missteps would hurt the company and its stock.